Upload
phungdat
View
220
Download
1
Embed Size (px)
Citation preview
Global Fund support for strengthening TB Control and PMDT
Joint Partners Forum, Geneva 27-30 April, 2015
content
• TB Portfolio
• NFM: Achievements and challenges for TB and PMDT
1
2
Grant Portfolio 2002-2014
Global Fund reports, 2014
30.5
16.5
8.3
4.8
0.7 0.2 0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
Total HIV/AIDS Malaria TB HSS Other
GF Signed Grants ($US Billion)
0 5,0002,500
Kilometers ´
Global Fund Financing
Tuberculosis Grants: Coverage by Country
US$ 4.8 billion (Signed Amount)
US$ 3.8 billion (Disbursed Amount)
- 109 country programs,
- 1 multicountry program. Source: Global Fund Grant Data
Source: Global TB reports, 2013
Global Fund Financing for TB
75%
25%
Global Fund
OtherInternationalfunders
Funding for TB – 2002-2014
5
Top 10 countries
India
China
Indonesia
Pakistan
Bangladesh
Philippines
Ethiopia
Nigeria
Myanmar
Russian Federation
AELAC - EECA 15%
AELAC - LAC 6%
AELAC - SEA 7%
AME-CA 3%
AME-MENA
6%
AME-SEA 4% AME-WA
3%
High Impact - Africa I
8%
High Impact - Africa II
9%
High Impact - Asia 39%
Trends in TB Disbursements 2002-2013
0
100,000,000
200,000,000
300,000,000
400,000,000
500,000,000
600,000,000
700,000,000
800,000,000
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Disbursements
Agenda
• TB Portfolio
• NFM: Achievements and challenges for TB and PMDT
1
2
Disease Split - NFM
50%
32%
18%
HIV/AIDS Malaria TB
8
9
NFM Summary: TB Submissions to Date
10
May (W1) June (W2) August (W3) October (W4) January (W5) April (W6) July (W7) Sept (W8)
TB-HIV
• Haiti
TB
• Bangladesh
• Cambodia
• Philippines
• Zimbabwe
TB-HIV
• Thailand
• Ukraine
• Zambia
TB
• Afghanistan
• Armenia
• Bhutan
• Comoros
• Multicountry
Western
Pacific
• Moldova
• Pakistan
• Papua New
Guinea
TB-HIV
• Chad
• Congo (DR)
• India
• Nigeria
• Panama
• Rwanda
• Sudan
• Viet Nam
• Zambia
TB
• Bulgaria
• Korea (DPR)
• Fiji
• Lao (PDR)
• Pakistan
• Romania
• Sao Tome
and Principe
• Solomon
Islands
• South Sudan
• Sri Lanka
TB-HIV
• Burkina Faso
• Cameroon
• Ethiopia
• Ghana
• Haiti
• Mozambique
• Sudan
• Swaziland
• Tanzania
• Togo
• Uganda
• Zanzibar
TB
• Azerbaijan
• Fiji
• Gambia
• Tajikistan
• Uzbekistan
TB-HIV
• Belize
• Botswana
• Burundi
• Cape Verde
• Djibouti
• India
• Kenya
• Kyrgyzstan
• Malawi
• Panama
• Suriname
• Togo
• Zanzibar
Regional
• ESCA-HC
• IGAD
• PAS
• SARCM
TB
• Belarus
• Benin
• Côte d’Ivoire
• Dominican
Republic
• Egypt
• El Salvador
• Gabon
• Guatemala
• Guyana
• Kosovo
• Madagascar
• Mauritania
• Nicaragua
• Niger
• Palestine
• Paraguay
• Peru
• Senegal
• Timor-Leste
TB-HIV
• Albania
• Angola
• Cameroon
• Congo
• Indonesia
• Lesotho
• Mali
• Multicountry
Caribbean
TB
• Georgia
• Guinea-
Bissau
• Liberia
• Somalia
• Syrian Arab
Republic
• Turkmenistn
TB-HIV
• South Africa
TB
• Bolivia
• Eritrea (TBC)
• Guinea
• Honduras
• Mongolia
• Morocco
(TBC)
• Multicountry
Americas
(TBC)
• Nepal
• Yemen
TB-HIV
• Central
African
Republic
• Namibia
(TBC)
• Sierra Leone
1 7 16 19 18 26 7 12
*Iteration
US$523 million Incentive Funding Awarded in
Windows 1- 4
Incentive funding breakdown by disease
(US$ millions)
400
300
0
100
250
150
50
350
450
200
500
550
TB TB/HIV
US$ 61
HIV/AIDS
US$
230
TB/HIV
Total
US$26
523
(100%)
As of 20/12/ 2015
11
30% 25% of awarded
incentive funding
for TB
Requested Funding by Module - TB Grants In selected 7 Board approved countries totaling US$285 million
12
TB Care and Prevention
26%
MDR-TB 18%
PSM 8%
HIS/M&E 6%
Health Community Workforce
6%
TB-HIV 5%
Program Management
23%
CSS 4%
Service Delivery
2%
Removing Legal Barriers
to Access 1%
Other 1%
50 concept notes reviewed
• 39 (78%) recommended for
grant-making
• 11 (22%) recommended for
iteration with TRP
This is a consistent percentage of
iterations requested as in third
window
6 concept notes discussed in fourth
window from past windows
• 1 from first window
• 2 from second window
• 3 from third window
All iterations moved to grant-making
From past windows Window 4
• Continued positive examples of rapid iteration with 100% success rate
• Large number of concept notes were strategically focused and evidence based
• Higher percentage of concept notes have clarifications to be cleared by the TRP
13
Summary of window 4 review outcomes
Lessons from review of Concept Notes
• Prioritization of interventions • NSP and Concept Note
• Basic services and scale-up
• Case detection for drug sensitive and MDR-TB scale-up • Challenge in setting targets
• Flattening/decreasing trend
• MDR-TB
• Estimates and prevalence survey results
• Laboratory services linking new diagnostics and lab plans
• Limited linkages and integration with other health programs • Integrated approach to MDR-TB care
• Balance diagnosis and treatment capacity
• Model of care
• Quality of treatment
• Joint TB and HIV programming
14
Framework for joint programming and joint concept note
HIV-specific TB-Specific Collaborative
TB/HIV activities
16
Months from submission to communication of results
17
Overall experience in applying
for funding from the Global
Fund
(N=191)
20%
61%
16%
3%
Very poor Poor Good Very Good
41%
29%31%
44%
50%47%
4%9%11%
4%5%5%8%6%6%
The Global Fund’s
increased focus on
inclusiveness
encouraged better
engagement with key
stakeholders (N=176)
The program split
discussion in
countries led to
better allocation
of resources
(N=117)
Was the application
process better than
the rounds-
based (N=188)
Evolve the funding model 77% of participants found new funding model an improvement
Timeline for strategy development 2017-2021
2014 2015 2016
9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 7
Board
approval of
GF Strategy
Board approval
of goals and
strategic objectives
Analytical work
Consultations
Replenishment
preparatory meeting
(tbc)
Oct 2014
SIIC
1st SIIC
2015
3rd SIIC
2015
1st SIIC
2016
2nd SIIC
2015
2nd SIIC
2016
5th
Replenishment
(tbc)
18
Thanks
19